Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Abstract Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on th...

Full description

Bibliographic Details
Main Authors: Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer
Format: Article
Language:English
Published: Nature Portfolio 2022-04-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00406-0

Internet

https://doi.org/10.1038/s41523-022-00406-0

Similar Items